Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
Description, Clinical trials & Overview
Explore the main themes, entities and connections around Bococizumab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
ldl development pfizer pcsk9 cholesterol drug code levels antibodies reduce patients trials antibody usan phase significantly anti-drug rn316 targeting withdrew
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Bococizumab | ATC code | none | 1.00 | infobox |
| Bococizumab | CAS Number | 1407495-02-6 | 1.00 | infobox |
| Bococizumab | ChEMBL | ChEMBL3137349 | 1.00 | infobox |
| Bococizumab | ChemSpider | none | 1.00 | infobox |
| Bococizumab | Formula | C6414H9918N1722O2012S54 | 1.00 | infobox |
| Bococizumab | IUPHAR/BPS | 7730 | 1.00 | infobox |
| Bococizumab | KEGG | D10621 Y | 1.00 | infobox |
| Bococizumab | Legal status | Investigational | 1.00 | infobox |
| Bococizumab | Molar mass | 145077.18 g·mol−1 | 1.00 | infobox |
| Bococizumab | PubChem SID | 194168554 | 1.00 | infobox |
| Bococizumab | Routes of administration | Subcutaneous injection | 1.00 | infobox |
| Bococizumab | Source | Humanized (from mouse) | 1.00 | infobox |
| Bococizumab | Target | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | 1.00 | infobox |
| Bococizumab | Type | Whole antibody | 1.00 | infobox |
| Bococizumab | UNII | 45M75JVK38 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.